<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720238</url>
  </required_header>
  <id_info>
    <org_study_id>D1211000039120003</org_study_id>
    <nct_id>NCT01720238</nct_id>
  </id_info>
  <brief_title>Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis</brief_title>
  <official_title>Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <authority>China: Beijing Municipal Science and Technology Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Though newly reported HBV infection and HBsAg prevalence in China have greatly decreased,
      patients who had been chronically infected with HBV, especially those with liver cirrhosis
      cause great burden on public health care. In view of economic development level, drug
      availability and lack of independent health economics evidence, the investigators are still
      unable to give specific guidelines for HBV related compensated liver cirrhosis in China.
      Therefore, the investigators aim to investigate clinical effects and cost-effectiveness of
      two early anti-viral therapy strategies on HBV related compensated liver cirrhosis through
      this prospective, open-label, multicenter and nonrandomized study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Decompensation rate of liver cirrhosis</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>presence of ascites, variceal hemorrhage, hepatic encephalopathy and HCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>child-pugh score</measure>
    <time_frame>1,2 and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBVDNA undetected</measure>
    <time_frame>1,2 and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver elasticity</measure>
    <time_frame>1, 2, and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality score</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Entecavir Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Lamivudine plus Adefovir Dipivoxil Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5mg qd</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>other manufacturers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine plus Adefovir Dipivoxil</intervention_name>
    <description>Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Heptodin</other_name>
    <other_name>other manufactures</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum,plasma and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        compensated HBV Related liver cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  aged 18-70 years

          -  clinical diagnosis of compensated liver cirrhosis

               1. liver biopsy showing cirrhosis

               2. endoscopy: esophageal varices , exclusion of noncirrhotic portal hypertension

               3. if no biopsy or endoscopy ，should  meet two of the four:

                    -  Imaging(US, CT or MRI, et al) showing Surface nodularity： Echogenecity
                       （spleen pachydiameter &gt; 4.0cm or&gt; 5 costal region）

                         -  PLT &lt; 100×10 &lt; 9 &gt;/L，no other interpretation

                              -  ALB &lt; 35.0 g/L, or INR &gt; 1.3, or CHE &lt; 5.0KU/L

                                   -  Liver stiffness measurement value &gt; 12.4 kpa

          -  HBeAg(+)with HBVDNA &gt; 10 &lt; 3 &gt; IU/mL or HBeAg(-) wtih HBVDNA &gt; 102 IU/mL

        Exclusion Criteria:

          -  patient with decompensated liver cirrhosis:presence of ascites, variceal
             hemorrhage,hepatic encephalopathy

          -  allergic to any ingredients of the drugs

          -  patient complicated with alcoholic liver disease, autoimmune liver disease, heretic
             liver disease, drug induced liver disease,nonalcoholic liver disease or other chronic
             liver disease.

          -  AFP &gt; 100ng/ml or Cr &gt; 1.5×ULN

          -  pregnant woman

          -  patient with severe disease or other organ failure

          -  patient with any tumors

          -  patient with sever mental disease.

          -  patients with any disease or condition which the investigator or treating physician
             feels would interfere with the trial or the safety of the subject
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ji Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong ji Jia, Doctor</last_name>
    <phone>8610-63139816</phone>
    <email>jiamd@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong You, Doctor</last_name>
    <phone>8610-63139019</phone>
    <email>youhong30@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning X Wu, Doctor</last_name>
      <phone>8610-63138665</phone>
      <email>wuxiaoningbs@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan X Xu, Doctor</last_name>
      <phone>8613001185762</phone>
      <email>yangpin@public.bta.net.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PeKing University People's Hopital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Ma, Doctor</last_name>
      <phone>8613671090481</phone>
      <email>mahui_wj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo H Ding, Doctor</last_name>
      <phone>8613699119545</phone>
      <email>Lilei_1978@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing X Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng G Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Y Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>November 1, 2012</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jia Ji-Dong</investigator_full_name>
    <investigator_title>Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Compensated Liver Cirrhosis</keyword>
  <keyword>Early Antiviral Therapy</keyword>
  <keyword>Cost Effectiveness</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
